# A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects

> **NCT03093714** · PHASE1 · COMPLETED · sponsor: **Flatley Discovery Lab LLC** · enrollment: 27 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** FDL169
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03093714
- **Lead sponsor:** Flatley Discovery Lab LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-23
- **Primary completion:** 2018-04-03
- **Final completion:** 2018-04-03
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2018-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03093714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03093714, "A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03093714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*